Table 2.
Treatment characteristics, outcome and safety profile.
| Non-vitrectomized eyes (n = 130) | Vitrectomized eyes (n = 106) | |||
|---|---|---|---|---|
| Naive eyes (n = 71) | Refractory eyes (n = 59) | Naive eyes (n = 76) | Refractory eyes (n = 30) | |
| Follow-up period, months, mean ± SD | 24.0 ± 0.0 | 24.0 ± 0.0 | 24.3 ± 8.8 | 28.8 ± 17.0 |
| No. of DEX-I during follow-up, mean ± SD | 3.9 ± 0.5 | 3.1 ± 1.2 | 3.1 ± 1.1 | 3.9 ± 2.9 |
| Baseline VA, logMAR, mean ± SD | 0.59 ± 0.15 | 0.61 ± 0.19 | 0.57 ± 0.17 | 0.58 ± 0.40 |
| VA at last FU, logMAR, mean ± SD | 0.36 ± 0.14 | 0.47 ± 0.23 | 0.36 ± 0.16 | 0.55 ± 0.41 |
| VA change baseline-last FU, logMAR, mean ± SD | −0.23 ± 0.20 | −0.15 ± 0.25 | −0.21 ± 0.15 | −0.03 ± 0.29 |
| CST at baseline, µm, mean ± SD | 583 ± 94 | 565 ± 107 | 693 ± 159 | 490 ± 133 |
| CST at last FU, µm, mean ± SD | 279 ± 61 | 313 ± 125 | 256 ± 41 | 317 ± 85, n = 26 |
| CST change baseline-last FU, µm, mean ± SD | −304 ± 117 | −252 ± 180 | −437 ± 181 | −173 ± 170, n = 26 |
| Eyes with additional anti-VEGF injections during FU, n (%) | 1 (1.4) | 10 (16.9) | 2 (2.6) | 6 (20.0) |
| Eyes that underwent cataract surgery within FU, n (% of phakic eyes) | 15/16 (93.8) | 7/22 (31.8) | 11/12 (91.7) | 5/12 (41.7) |
| Eyes that needed IOP-lowering treatment within FU, n (%) | 5/70 (7.1) | 13/57 (22.8) | 4 (5.3) | 9 (30.0) |
CST central subfield thickness, FU follow-up, VA visual acuity.